Prime Medicine to Present at Three Major Biotech Conferences in March

GlobeNewswire Inc.GlobeNewswire Inc.
|||1 min read
Key Takeaway

Prime Medicine will present at three major biotech conferences in March 2026, including TD Cowen and Citizens Life Sciences, with webcasts available afterward.

Prime Medicine to Present at Three Major Biotech Conferences in March

Prime Medicine has confirmed its participation in three prominent healthcare and biotechnology investor conferences scheduled for March 2026. The company's management team will engage with institutional investors through multiple formats, including fireside chat presentations and one-on-one meetings with portfolio managers and analysts.

The firm will present at the TD Cowen Health Care Conference and the Citizens Life Sciences Conference, where executives will participate in moderated fireside chats designed to discuss the company's pipeline, strategic initiatives, and market positioning. Additionally, Prime Medicine will host individual investor meetings at the Jefferies Biotech on the Beach Summit, providing opportunities for detailed discussions with selective institutional investors.

Webcasts of the fireside chat sessions will be made available on Prime Medicine's investor relations website, enabling broader access to the presentations for shareholders and market observers unable to attend the events in person. This investor engagement strategy is typical for biotech firms seeking to maintain ongoing communication with capital markets participants regarding company developments and financial performance.

Source: GlobeNewswire Inc.

Back to newsPublished Feb 25

Related Coverage

Benzinga

Atossa Therapeutics Advances (Z)-Endoxifen Pipeline With FDA Orphan Designations

Atossa Therapeutics reported Q1 2026 expenses of $9.9M, secured FDA orphan drug designation for lead candidate (Z)-endoxifen in rare diseases.

ATOS
Benzinga

Phoenix Asia Stock Surges 47% After Announcing $1B Pharma Acquisition

Phoenix Asia Holdings ($PHOE) surged 47% after-hours following $1B deal to acquire ACEA Pharma, pivoting from construction into oncology and autoimmune drug development.

PHOE
GlobeNewswire Inc.

Assembly Biosciences Advances Pipeline With $226.6M Cash Runway Into 2028

Assembly Biosciences reports Q1 2026 results with $226.6M cash runway into 2028, completing Phase 1b herpes studies and advancing hepatitis delta candidate toward Phase 2.

GILDASMB
Benzinga

Roche Bets $1.05B on PathAI to Fortify Digital Pathology Arsenal

Roche to acquire digital pathology company PathAI for up to $1.05 billion, paying $750 million upfront with $300 million in milestone payments to strengthen AI diagnostics capabilities.

RHHBY
GlobeNewswire Inc.

PARP Inhibitor Pipeline Surges: 25+ Pharma Giants Race to Expand Cancer Drug Arsenal

Over 25 pharma companies develop 30+ PARP inhibitors in trials, with AstraZeneca and Gilead leading expansion into multiple cancer indications including glioblastoma and prostate cancer.

AZNGILDALLR
GlobeNewswire Inc.

Incannex Healthcare Wins MedTech Prize for Sleep Apnea Drug IHL-42X

Incannex Healthcare wins MedTech Breakthrough Award for IHL-42X sleep apnea therapy, validated by successful Phase 2 trial results showing significant improvements in key endpoints.

IXHL